Timothy J. Triche

Van Andel Institute

Full Professor(heuristic)

Sarcoma Diagnosis and Treatment · Pulmonary and Respiratory Medicine

Compare more Pulmonary and Respiratory Medicine professors.

h-index82
i10-index220
Publications555
Citations25,113

Grants

10 total · 0 active

NIH #R01AI171984

The roles of genetics, hormones, and gender in sexually dimorphic immune response

Amount
$600K–$700K
Period
2022-09-01 → 2026-08-31
PIs
3

Awarded at VAN ANDEL RESEARCH INSTITUTE

NIH #R42CA281707

Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

Amount
$1M–$2M
Period
2023-08-08 → 2026-07-31
PIs
2

Awarded at NANOVALENT PHARMACEUTICALS, INC.

NIH #R03CA290259

Dissecting the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition

Amount
$300K–$400K
Period
2024-07-01 → 2026-06-30
PIs
1

Awarded at VAN ANDEL RESEARCH INSTITUTE

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

10 total · 0 active

NIH #R01AI171984

The roles of genetics, hormones, and gender in sexually dimorphic immune response

Amount
$600K–$700K
Period
2022-09-01 → 2026-08-31
PIs
3

Awarded at VAN ANDEL RESEARCH INSTITUTE

NIH #R42CA281707

Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

Amount
$1M–$2M
Period
2023-08-08 → 2026-07-31
PIs
2

Awarded at NANOVALENT PHARMACEUTICALS, INC.

NIH #R03CA290259

Dissecting the role of germline genetic variation and viral exposures as determinants of hematological disease predisposition

Amount
$300K–$400K
Period
2024-07-01 → 2026-06-30
PIs
1

Awarded at VAN ANDEL RESEARCH INSTITUTE

NIH #R01CA257610

Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer

Amount
$700K–$800K
Period
2021-02-09 → 2026-01-31
PIs
3

Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA

NIH #R44CA233128

NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy

Amount
$1M–$2M
Period
2018-09-14 → 2021-04-30
PIs
2

Awarded at NANOVALENT PHARMACEUTICALS, INC.

NIH #R41CA203457

Nanoparticle Delivery System for Ewing Sarcoma Treatment

Amount
$200K–$300K
Period
2016-04-15 → 2018-03-31
PIs
2

Awarded at NANOVALENT PHARMACEUTICALS, INC.

NIH #RC2CA148216

Translation of Predictive Cancer Biomarkers into Clinical Practice

Amount
$1M–$2M
Period
2009-09-29 → 2011-08-31
PIs
2

Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES

NIH #U01CA114757

Diagnostic and Prognostic Sarcoma Signatures

Amount
$1M–$2M
Period
2005-09-27 → 2010-05-31
PIs
1

Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES

NIH #U01CA088199

GENE EXPRESSION IN SARCOMAS OF CHILDHOOD AND ADOLESCENCE

Amount
$1M–$2M
Period
2000-09-20 → 2005-01-31
PIs
1

Awarded at CHILDREN'S HOSPITAL OF LOS ANGELES

NIH #P30CA014089

Microarray Core Facility

Amount
$400K–$500K
Period
— → —
PIs
1

Awarded at UNIVERSITY OF SOUTHERN CALIFORNIA

Recent Public Signals

  1. New paper: Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS (Blood Neoplasia)2026-05-05
  2. New preprint: Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer2025-12-02

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0003-4869-8826

Professor Insights

Career Trajectory